BACKGROUND: The expansion of the indications for endoscopic submucosal dissection (ESD) to include early @entity356 has enabled extensive resection. However, post-ESD @entity850 after large resections applied to the @entity356 or pylorus is often difficult to manage. The aim of this study was to evaluate the benefit of oral @entity617 and @entity2713 injection for @entity850 after gastric ESD. METHODS: Eight @entity1 who underwent ESD for large neoplastic lesions that extended more than three-fourths of the luminal circumference were enrolled in this study. Four @entity1 underwent ESD for @entity356 , and four @entity1 were treated for pyloric lesions. To prevent post-ESD stricture, oral @entity617 was started at 30 mg daily on the second day after ESD and then tapered gradually in two cases, while topical injection of 80 mg @entity2713 was performed once immediately after ESD in six cases. @entity384 ( @entity384 ) was used for stricture-related symptoms or signs including @entity390 , @entity391 , or food residuals observed on endoscopy. @entity384 was also applied if a 10-mm-diameter endoscope was not able to pass through the lumen. The incidence of @entity850 , the frequency and period required for @entity384 , the duration required for @entity1066 after ESD, and the incidences of @entity548 and perforation were assessed. RESULTS: One of the eight @entity1 had post-ESD @entity850 requiring @entity384 . The median @entity1066 period after ESD was 87.5 (range, 56-133) days. No @entity1 experienced @entity548 or perforation. There were no adverse events due to @entity134 therapy. CONCLUSIONS: The results of the present study showed the safety and usefulness of @entity134 therapy for management of @entity850 after large ESD in the @entity356 or pylorus.

Oral @entity617 and XXXX injection for @entity356 after endoscopic submucosal dissection.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity548 :: ('MESH:D006470', 'Disease') :: ['post-procedural bleeding'] @entity384 :: ('MESH:D002311', 'Disease') :: ['EBD', 'Endoscopic balloon dilatation'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer healing'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cardia cancer', 'gastric cardia', 'gastric cancers'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone'] @entity2713 :: ('MESH:D014221', 'Chemical') :: ['triamcinolone']
@entity2713 :: (MESH:D014221,Chemical) :: ['triamcinolone']
